Tidt.Bo
TIDT.BO operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.
Business. TIDT.BO operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
TIDT.BO operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.
TIDT.BO has a debt-to-equity ratio of 0.84, indicating a moderate level of leverage, and a current ratio of 1.69, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company reported negative operating cash flow of -102,417,000 INR, which raises concerns about its ability to fund operations from core business activities. Free cash flow stands at 48,879,000 INR, which is positive but relatively small compared to the company's total liabilities of 915,486,000 INR.
The company's profitability is reflected in a return on equity (ROE) of 18.23% and a return on assets (ROA) of 7.53%, both of which are strong indicators of efficient use of equity and assets. These figures suggest that TIDT.BO is generating solid returns for its shareholders and effectively utilizing its asset base to generate profits.
TIDT.BO's revenue is concentrated in the pharmaceuticals segment, with no disclosed geographic diversification in the provided data. The company's revenue of 869,647,000 INR is entirely attributed to its core pharmaceutical operations. There is no information on geographic revenue distribution, which could indicate a potential concentration risk if the company is heavily reliant on a single market.
Looking ahead, TIDT.BO is expected to maintain its current revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's capital expenditure of -110,995,000 INR indicates a net outflow for investments in long-term assets, which could be a sign of expansion or modernization efforts. However, the negative operating cash flow suggests that the company may need to rely on external financing to fund these investments.
The risk assessment for TIDT.BO highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could limit its financial flexibility. There are no immediate signs of dilution pressure, as the number of shares outstanding remains unchanged between basic and diluted shares. However, the negative operating cash flow and reliance on external financing could pose challenges in the near term.
There are no recent events or filings disclosed in the provided data that would significantly impact TIDT.BO's operations or financial position. The company's financial statements do not indicate any material changes in its business strategy or operational performance in the most recent reporting period.
- TIDT.BO has a strong return on equity (18.23%) and return on assets (7.53%), indicating efficient use of equity and assets.
- The company's debt-to-equity ratio of 0.84 suggests moderate leverage, but its negative operating cash flow raises concerns about liquidity.
- TIDT.BO's revenue is entirely concentrated in the pharmaceuticals segment, with no disclosed geographic diversification.
- The company's free cash flow is positive but relatively small compared to its total liabilities.
- TIDT.BO has a low dilution risk, as the number of shares outstanding remains unchanged between basic and diluted shares.
- The company's net cash position is negative after accounting for total debt, which could limit its financial flexibility.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- TIDT.BO Market data — financials · 2026-05-29
Ownership & reference
Leadership
- Hardik Jigishkumar DesaiExecutive Chairman of the Board